BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31565143)

  • 1. Frequency of maintenance hemodialysis patients meeting K/DOQI criteria for serum calcium, phosphorus, calcium phosphorus product and PTH levels; a single institutional experience from Pakistan: a cross sectional study.
    Janjua TK; Mukhtar KN; Naveed AK; Ahmed EB; Rehan M
    Pan Afr Med J; 2019; 33():183. PubMed ID: 31565143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of bone mineral metabolism derangements by K/DOQI guidelines in haemodialysis patients at Rawalpindi.
    Khan DA; Fatima-Tuz-Zuhra ; Khan FA; Saif I
    J Pak Med Assoc; 2009 Feb; 59(2):64-7. PubMed ID: 19260564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
    J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them?
    Wei M; Taskapan H; Esbaei K; Jassal SV; Bargman JM; Oreopoulos DG
    Int Urol Nephrol; 2006; 38(3-4):739-43. PubMed ID: 17160632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
    Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
    J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle.
    Al Aly Z; González EA; Martin KJ; Gellens ME
    Am J Nephrol; 2004; 24(4):422-6. PubMed ID: 15308874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are CSN and NKF-K/DOQI mineral metabolism guidelines for hemodialysis patients achievable? Results from a provincial renal program.
    Wazny LD; Raymond CB; Lesperance EM; Bernstein KN
    CANNT J; 2008; 18(2):36-41, 44-50; quiz 42-3, 51-2. PubMed ID: 18669010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influences of method of calcium correction and the timing of blood collection on application of the K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Japan.
    Yokoyama K; Katoh N; Kasai K; Kubo H; Murai S; Shoji R; Imamura N; Saika S; Yumita S; Ishida M; Takasu S; Kono T; Yoshida Y; Wakabayashi T; Kimua Y; Hosoya T
    Ther Apher Dial; 2006 Jun; 10(3):257-61. PubMed ID: 16817790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achievement of NKF/K-DOQI recommended target values for bone and mineral metabolism in incident hemodialysis patients: results of the FARO-2 cohort.
    Cozzolino M; Messa P; Brancaccio D; Cannella G; Bolasco P; Di Luca M; Costanzo AM; Paparatti Ud; Festa V; Gualberti G; Mazzaferro S;
    Blood Purif; 2014; 38(1):37-45. PubMed ID: 25277167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
    Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
    Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.
    Noordzij M; Korevaar JC; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT;
    Am J Kidney Dis; 2005 Nov; 46(5):925-32. PubMed ID: 16253734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of calcium and phosphorus metabolism in hemodialysis patients in Tehran Province, Iran.
    Mahdavi-Mazdeh M; Zamyadi M; Norouzi S; Heidary Rouchi A
    Iran J Kidney Dis; 2007 Jul; 1(1):25-8. PubMed ID: 19357440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between pruritus and serum concentrations of parathormone, calcium and phosphorus in hemodialysis patients.
    Tajbakhsh R; Joshaghani HR; Bayzayi F; Haddad M; Qorbani M
    Saudi J Kidney Dis Transpl; 2013 Jul; 24(4):702-6. PubMed ID: 23816717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study.
    Kimata N; Albert JM; Akiba T; Yamazaki S; Kawaguchi T; Fukuhara S; Akizawa T; Saito A; Asano Y; Kurokawa K; Pisoni RL; Port FK
    Hemodial Int; 2007 Jul; 11(3):340-8. PubMed ID: 17576300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CA-P control in haemodialysis and K/DOQI guidelines].
    Rivera F; Sánchez de la Nieta MD; Echarri R; Anaya S; Carreño A; Vozmediano MC; Alcaide MP
    Nefrologia; 2006; 26(3):351-7. PubMed ID: 16892824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of percutaneous ethanol injection therapy for secondary hyperparathyroidism in patients on hemodialysis as evaluated by parathyroid hormone levels according to K/DOQI guidelines.
    Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):48-52. PubMed ID: 15828906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to K/DOQI practice guidelines for bone metabolism and disease.
    Hoy T; Fisher M; Barber B; Borker R; Stolshek B; Goodman W
    Am J Manag Care; 2007 Nov; 13(11):620-5. PubMed ID: 17988187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.